Showing results (2401-2410 of 2,413) with videos related to

Sort By:
Pageof 242
Annals of Surgery|September 5, 2020
mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active TumorsAndreas A Schnitzbauer, Natalie Filmann, René Adam, et al.
The Lancet. Oncology|November 18, 2022
European Groundshot-addressing Europe's cancer research challenges: a Lancet Oncology CommissionMark Lawler, Lynne Davies, Simon Oberst, et al.
Blood Advances|May 7, 2025
Pivotal Results of SELECT-MDS-1 Phase 3 Study of Tamibarotene with Azacitidine in Newly Diagnosed Higher-Risk MDSAmy E DeZern, Sylvain Thepot, Stéphane De Botton, et al.
Journal of the American Academy of Dermatology|February 1, 2024
Cumulative incidence and risk factors for cutaneous squamous cell carcinoma metastases in organ transplant recipients: The Skin Care in Organ Transplant Patients in Europe-International Transplant Skin Cancer Collaborative metastases study, a prospective multicenter studyEstella de Jong, Roel Genders, Catherine A Harwood, et al.
BMC Cancer|May 13, 2010
A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinomaAndreas A Schnitzbauer, Carl Zuelke, Christian Graeb, et al.
ESMO Open|August 30, 2017
The European Cancer Patient's Bill of Rights, update and implementation 2016Mark Lawler, Ian Banks, Kate Law, et al.
Frontiers in Immunology|January 31, 2018
Minimum Information about T Regulatory Cells: A Step toward Reproducibility and StandardizationAnke Fuchs, Mateusz Gliwiński, Nathali Grageda, et al.
Transplantation|November 12, 2015
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 TrialEdward K Geissler, Andreas A Schnitzbauer, Carl Zülke, et al.
Lancet (London, England)|May 25, 2020
Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trialsBirgit Sawitzki, Paul N Harden, Petra Reinke, et al.
Cancer Discovery|October 12, 2021
Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional RespondersChristoph Kornauth, Tea Pemovska, Gregory I Vladimer, et al.
Pageof 242